Ind-Swift Laboratories Limited — PPTs, 17-08-2026: Investor Presentation

**1. Business Performance:**

Ind-Swift Labs reported strong Q1FY27, reflecting its transformation into a focused Finished Dosage Formulation (FDF) manufacturer. Operating EBITDA jumped 2.85x YoY to ₹33.32 Cr, with margins at 17.91%. Revenue grew 21.16% YoY to ₹186.08 Cr, and PAT (excluding exceptional items) surged 2.04x YoY to ₹24.68 Cr, with PAT margin at 13.26%. This highlights improved efficiency and business mix.

**2. Growth Drivers or Strategy:**

The company strategically focuses on higher-margin formulations, having become a pure-play FDF entity after divesting its API unit for ₹1,650 Cr, making it net debt-free. Growth will come from expanding domestic high-margin Ethical and Own-Brand segments, alongside deeper international penetration via own-brands and strategic partnerships.

**3. Recent Developments:**

Q1FY27 saw commercialization of CDMO partnerships/own-brands with Viatris (Europe), Manx (UK), and Arrotex (Australia), projected to add ₹200-220 Cr in FY27 revenue. New products, Ibuprofen Sachet (Europe) and Macrogol Sachet (UK/Australia), were launched. The Samba facility upgrade to EU-GMP standards is underway to boost export capabilities. Global product registrations now stand at 850+, with dossiers filed reaching 2,100+.

**4. Key Financial Metrics:**

For Q1FY27, total revenue was ₹193.71 Cr. Operating EBITDA stood at ₹33.32 Cr, showing a 78.28% QoQ rise, while PAT was ₹24.68 Cr, up 22.84% QoQ.

**5. Management Commentary / Outlook:**

Management anticipates FY27 revenue growth over 50%, targeting a medium-term revenue CAGR of 20-25% and EBITDA margin expansion of 600-800 bps. Topline is targeted at ₹1,200+ Cr by FY29, with CDMO tripling in three years. Domestic business is expected to grow 15-20% annually.